Asieris(SH:688176) Xin Lang Cai Jing·2025-08-28 02:03Core Insights - On August 27, Yahui Pharmaceutical experienced a decline of 4.78% with a trading volume of 276 million yuan [1] - The company reported a financing buy-in amount of 30.41 million yuan and a financing repayment of 38.24 million yuan, resulting in a net financing buy of -7.83 million yuan [1] - As of August 27, the total margin balance for Yahui Pharmaceutical was 240 million yuan, representing 4.76% of its market capitalization [1] Financing Summary - On August 27, Yahui Pharmaceutical had a financing buy-in of 30.41 million yuan, with a current financing balance of 240 million yuan, which is above the 90th percentile of the past year [1] - The company had no short selling activity on August 27, with a short selling balance of 0.00 shares, indicating a high level of short selling availability [1] Company Overview - Yahui Pharmaceutical, established on March 16, 2010, is located in the Pudong New Area of Shanghai and was listed on January 7, 2022 [1] - The company's main business involves the research, production, and sales of innovative drugs, with 94% of its revenue coming from anti-tumor products [1] Financial Performance - As of March 31, Yahui Pharmaceutical had 24,900 shareholders, a decrease of 4.29% from the previous period, with an average of 15,167 circulating shares per shareholder, an increase of 6.40% [2] - For the period from January to March 2025, the company reported a revenue of 61.11 million yuan, a year-on-year increase of 151.24%, while the net profit attributable to the parent company was -83.53 million yuan, a decrease of 0.82% year-on-year [2] Institutional Holdings - As of March 31, 2025, among the top ten circulating shareholders of Yahui Pharmaceutical, Penghua Medical Technology Stock A (001230) ranked as the eighth largest shareholder, holding 5.65 million shares, unchanged from the previous period [2]